Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Journal of Indonesian Health Policy and Administration Jurnal Ekonomi Kesehatan Indonesia
Megraini, Amila
Unknown Affiliation
Decision Sciences, Operations Research & Management Economics, Econometrics & Finance Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Jurnal Ekonomi Kesehatan Indonesia

 1 
Economic Evaluation Of Cetuximab for Metastatic Colorectal Cancer (mCRC): A Protocol For Evidence Synthesis Putri, Septiara; Setiawan, Ery; Saldi, Siti Rizny F.; Chandra, Levina; Megraini, Amila; P, Vetty Yulianty
Jurnal Ekonomi Kesehatan Indonesia Vol. 3, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Colorectal cancer is fairly common compared to other cancers. The incidence and mortality rates are predicted to increase globally. In some cases, cancer can be potentially spread to another organ or metastatic. One of recent available targeted therapies for metastatic colorectal cancer (mCRC) patient is Cetuximab (Erbitux ®), combined with chemotherapy. Despite clinical effectiveness, there is the importance of the evidence related cost-effectiveness of therapy. This study aims to summary, synthesize, and systematically review the economic evaluation studies of Cetuximab for metastatic colorectal cancer (mCRC). Model based economic evaluation of Cetuximab for metastatic colorectal cancer will be searched and included in the review based on specific eligibility criteria. Several electronic databases that will be used: Medline, Embase, Cochrane, National Institute of Health Research (NIHR) Center for Reviews and Dissemination. Full economic evaluation evidence will be summarized and critically appraised using Drummond as well as (Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. In terms of analysis, we will qualitatively appraise and present the studies that meet our inclusion and exclusion criteria. We are expected to summarize the quality and capture the valuable insights related to health economic evaluation studies of Cetuximab for mCRC patient.
Co-Authors Athiyah, Athiyah Chandra, Levina Ery setiawan Farianti, Yuli Kurnia Sari Mangunsong, Emmy Ridhawaty Mukhlisa, Mazda Novi Nadjib, Mardiati Nurwahyuni, Atik P, Vetty Yulianty Padmasari, Indah Raksi Prastuti Soewondo putri, septiara Saldi, Siti Rizny F. Sayekti, Sekar Arum Handarbeni Wahyuningsih, Helmi Yunita Yunita